Susquehanna International Group, LLP Biogen Inc. Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

A detailed history of Susquehanna International Group, LLP transactions in Biogen Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 243,414 shares of BIIB stock, worth $56.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

243,414

Previous 78,590 209.73%

Holding current value

$56.4 Million

Previous $20.3 Million 158.1%

% of portfolio

0.01%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$212.02 - $267.71 $34.9 Million - $44.1 Million	164,824 Added 209.73%	243,414 $52.5 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $7.45 Million - $8.97 Million	-33,487 Reduced 29.88%	78,590 $20.3 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $18.6 Million - $21 Million	73,296 Added 189.0%	112,077 $28.8 Million
Q2 2023 Aug 11, 2023	SELL	$275.25 - $318.06 $14.1 Million - $16.3 Million	-51,337 Reduced 56.97%	38,781 $11 Million
Q1 2023 May 16, 2023	SELL	$256.56 - $292.34 $32.5 Million - $37 Million	-126,619 Reduced 58.42%	90,118 $25.1 Million

Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $12.7 Million - $15.5 Million	50,500 Added 30.38%	216,737 $60 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $12.4 Million - $17 Million	63,502 Added 61.81%	166,237 $44.4 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $31.4 Million - $37.4 Million	-167,627 Reduced 62.0%	102,735 $21 Million
Q1 2022 May 16, 2022	SELL	$193.77 - $244.14 $27.3 Million - $34.4 Million	-140,807 Reduced 34.25%	270,362 $56.9 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $4.5 Million - $5.79 Million	20,103 Added 5.14%	411,169 $98.6 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $3.89 Million - $5.08 Million	13,756 Added 3.65%	391,066 $111 Million
Q2 2021 Aug 11, 2021	BUY	$259.0 - $414.71 $30.2 Million - $48.4 Million	116,668 Added 44.76%	377,310 $131 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $101 Million - $119 Million	-417,254 Reduced 61.55%	260,642 $72.9 Million
Q4 2020 Feb 16, 2021	BUY	$236.26 - $355.63 $67.6 Million - $102 Million	286,040 Added 73.0%	677,896 $166 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $1.73 Million - $2 Million	-6,544 Reduced 1.64%	391,856 $111 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $62.1 Million - $82.3 Million	240,135 Added 151.73%	398,400 $107 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $16.8 Million - $21.3 Million	-62,521 Reduced 28.32%	158,265 $50.1 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $34.5 Million - $47.7 Million	-156,910 Reduced 41.54%	220,786 $65.5 Million
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $8.83 Million - $9.91 Million	40,618 Added 12.05%	377,696 $87.9 Million
Q2 2019 Aug 16, 2019	BUY	$219.29 - $241.72 $4.11 Million - $4.53 Million	18,739 Added 5.89%	337,078 $78.8 Million
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $65.3 Million - $71.9 Million	-297,559 Reduced 48.31%	318,339 $74.5 Million
Q1 2019 May 15, 2019	BUY	$216.71 - $338.96 $133 Million - $208 Million	614,098 Added 34116.56%	615,898 $146 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $1.8 Million - $2.28 Million	-6,456 Reduced 78.2%	1,800 $542,000
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $2.23 Million - $2.66 Million	-8,651 Reduced 51.17%	8,256 $2.4 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $1.1 Million - $1.56 Million	4,242 Added 33.49%	16,907 $4.63 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $3.9 Million - $4.36 Million	12,665	12,665 $4.03 Million

Others Institutions Holding BIIB

# of Institutions

1,046

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $33.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Biogen Inc. Transaction History